PM
50
-4
NTRS
35
-14
HCA
44
-2
CMS
54
-3
SLB
42
3
WFC
63
-2
HRL
50
-3
UPS
51
-4
F
40
-3
JCI
51
4
WBA
60
-6
NI
67
2
SHW
53
-2
IP
54
-2
TGNA
53
-3
BBY
48
2
DGX
29
-3
HSY
38
-7
AN
55
-2
PVH
62
2
PM
50
-4
NTRS
35
-14
HCA
44
-2
CMS
54
-3
SLB
42
3
WFC
63
-2
HRL
50
-3
UPS
51
-4
F
40
-3
JCI
51
4
WBA
60
-6
NI
67
2
SHW
53
-2
IP
54
-2
TGNA
53
-3
BBY
48
2
DGX
29
-3
HSY
38
-7
AN
55
-2
PVH
62
2
Financhill
Back

Intra-Cellular Therapies 10K Form

Buy
54

ITCI
Intra-Cellular Therapies

Last Price:
84.15
Seasonality Move:
17.89%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ITCI News And Ratings

See the #1 stock for the next 7 days that we like better than ITCI

ITCI Financial Statistics

Sales & Book Value

Annual Sales: $462.18M
Cash Flow: $-27.22M
Price / Cash Flow: 0
Annual Sales: $10.80
Price / Book: 7.77

Profitability

EPS (TTM): -0.87000
Net Income (TTM): $-86.37M
Gross Margin: $428.43M
Return on Equity: -10.58%
Return on Assets: -8.93%

Intra-Cellular Therapies Earnings Forecast

Key Intra-Cellular Therapies Financial Ratios

  • The Gross Profit Margin over the past 10 years for ITCI is 92.70%.
  • The Selling, General & Administrative Expenses for ITCI have been equal to 88.68% of Gross Profit Margin.
  • The Research & Development expenses have been 38.98% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Intra-Cellular Therapies Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ITCI
CUSIP: 46116X
Website: intracellulartherapies.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.66
Quick Ratio: 6.94

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 406.93

ITCI Technical Analysis vs Fundamental Analysis

Buy
54
Intra-Cellular Therapies (ITCI) is a Buy

Is Intra-Cellular Therapies a Buy or a Sell?